Next-Generation cDNA Screening for Oncogene and Resistance Phenotypes

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Shindoh, Nobuaki ^a,d   Yoda, Akinori ^a   Yoda, Yuka ^a   Sullivan, Timothy J ^a   Weigert, Oliver ^a   Lane, Andrew A ^a   Kopp, Nadja ^a   Bird, Liat ^a   Rodig, Scott J ^b,c   Fox, Edward A ^a,b   Weinstock, David M ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d ASTELLAS PHARMA INC   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5' UNTRANSLATED REGION; ANIMAL CELL; ARTICLE; CANCER CELL; CANCER RESISTANCE; CELL PROLIFERATION; CONTROLLED STUDY; DNA SCREENING; ERBB2 GENE; GAIN OF FUNCTION MUTATION; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; KRAS G12D GENE; LUNG CANCER; MOUSE; NONHUMAN; NRAS Q61K GENE; NUCLEOTIDE SEQUENCE; ONCOGENE; PHENOTYPE; PLASMID; POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

ANIMALS; CELL LINE; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; GENE LIBRARY; GENES, ERBB-2; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GENETIC VARIATION; MICE; ONCOGENES; PHENOTYPE; PROTEIN ISOFORMS; QUINAZOLINES;

MURINAE;

EID: 84868672787     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0049201     Document Type: Article

References (18)

1. Salmena L, Poliseno L, Tay Y, Kats L, Pandolfi PP, (2011) A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? Cell 146: 353-358.
2. Garraway LA, Janne PA, (2012) Circumventing cancer drug resistance in the era of personalized medicine. Cancer Discov 2: 214-226.
3. Okayama H, Berg P, (1982) High-efficiency cloning of full-length cDNA. Mol Cell Biol 2: 161-170.
4. Gubler U, Hoffman BJ, (1983) A simple and very efficient method for generating cDNA libraries. Gene 25: 263-269.
5. Lee F, Yokota T, Otsuka T, Gemmell L, Larson N, et al. (1985) Isolation of cDNA for a human granulocyte-macrophage colony-stimulating factor by functional expression in mammalian cells. Proc Natl Acad Sci U S A 82: 4360-4364.
6. Kitamura T, Onishi M, Kinoshita S, Shibuya A, Miyajima A, et al. (1995) Efficient screening of retroviral cDNA expression libraries. Proc Natl Acad Sci U S A 92: 9146-9150.
7. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, et al. (2007) Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448: 561-566.
8. Harvey RC, Mullighan CG, Chen IM, Wharton W, Mikhail FM, et al. (2010) Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. Blood 115: 5312-5321.
9. Hertzberg L, Vendramini E, Ganmore I, Cazzaniga G, Schmitz M, et al. (2010) Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group. Blood 115: 1006-1017.
10. Yoda A, Yoda Y, Chiaretti S, Bar-Natan M, Mani K, et al. (2010) Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci U S A 107: 252-257.
11. Colleoni GW, Bridge JA, Garicochea B, Liu J, Filippa DA, et al. (2000) ATIC-ALK: A novel variant ALK gene fusion in anaplastic large cell lymphoma resulting from the recurrent cryptic chromosomal inversion, inv(2)(p23q35). Am J Pathol 156: 781-789.
12. Rho JK, Choi YJ, Lee JK, Ryoo BY, Na II, et al. (2009) The role of MET activation in determining the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors. Mol Cancer Res 7: 1736-1743.
13. Zhou W, Ercan D, Chen L, Yun CH, Li D, et al. (2009) Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 462: 1070-1074.
14. Mitra D, Brumlik MJ, Okamgba SU, Zhu Y, Duplessis TT, et al. (2009) An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance. Mol Cancer Ther 8: 2152-2162.
15. Koivunen JP, Mermel C, Zejnullahu K, Murphy C, Lifshits E, et al. (2008) EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 14: 4275-4283.
16. Houghton AN, Real FX, Davis LJ, Cordon-Cardo C, Old LJ, (1987) Phenotypic heterogeneity of melanoma. Relation to the differentiation program of melanoma cells. J Exp Med 165: 812-829.
17. Kerbel RS, Man MS, (1984) Single-step selection of unique human melanoma variants displaying unusually aggressive metastatic behavior in nude athymic mice. Invasion Metastasis 4 Suppl 1: 31-43.
18. Rodig SJ, Mino-Kenudson M, Dacic S, Yeap BY, Shaw A, et al. (2009) Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res 15: 5216-5223.